Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25516101 | 0.98 | CASP2 (0.42) | CASP2MCL1TSHRCNR1NAAA | |
| SCHEMBL25516099 | 0.98 | CASP2 (0.42) | CASP2MCL1TSHRCNR1NAAA | |
| SCHEMBL16560390 | 0.92 | EPHX2 (0.45) | CASP2TSHRCNR1NAAAFAAH | |
| SCHEMBL21233609 | 0.91 | TSHR (0.49) | CASP2TSHRCNR1NAAAFAAH | |
| SCHEMBL24982767 | 0.90 | MEN1 (0.46) | CASP2TSHRCNR1NAAAFAAH | |
| SCHEMBL19544544 | 0.90 | MEN1 (0.46) | CASP2TSHRCNR1NAAAFAAH | |
| SCHEMBL16315752 | 0.88 | NAAA (0.47) | CNR1NAAAFAAHKMT2AMEN1 | |
| SCHEMBL24341463 | 0.88 | CASP2 (0.55) | CASP2TSHRCNR1NAAAFAAH | |
| SCHEMBL23711864 | 0.88 | SMN1; SMN2 (0.44) | CASP2MCL1TSHRCNR1NAAA | |
| SCHEMBL2122730 | 0.88 | CASP2 (0.50) | CASP2TSHRCNR1NAAAFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129614-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230149551-A1 | ARGININE METHYLTRANSFERASE 5 (PRMT5) DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2020206137-A1 | CDK2/5 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-8871894-B2 | Production method of polyhydroxyimide | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-20120094232-A1 | PRODUCTION METHOD OF POLYHYDROXYIMIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | CASP2 120/4885MCL1 1068/4885TSHR 4756/4885 |
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | ALK, ERBB2, PDGFRB | CASP2 2751/4885MCL1 136/4885TSHR 2390/4885 |
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | SNCA, ADRM1, UBE3C | CASP2 2795/4885MCL1 1313/4885TSHR 4450/4885 |
| US-20230149551-A1 | ARGININE METHYLTRANSFERASE 5 (PRMT5) DEGRADERS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | CASP2 3408/4885MCL1 206/4885TSHR 2274/4885 |
| US-20120094232-A1 | PRODUCTION METHOD OF POLYHYDROXYIMIDE | GRHPR, MRPL21, F12 | CASP2 3884/4885MCL1 2958/4885TSHR 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.